immunoprin 100 mg õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - asatiopriin - õhukese polümeerikattega tablett - 100mg 100tk; 100mg 50tk
mayzent
novartis europharm limited - siponimod fumaarhape - sclerosis multiplex, relapsing-remitting - selektiivsed immunosupressandid - mayzent on näidustatud ravi täiskasvanud patsientidel, kellel on sekundaarse progresseeruva sclerosis multiplex (spms) aktiivne haiguse tõendab ägenemiste või kujutise omadused põletikuline aktiivsus.
aciclovir accord infusioonilahuse kontsentraat
accord healthcare b.v. - atsikloviir - infusioonilahuse kontsentraat - 25mg 1ml 10ml 5tk; 25mg 1ml 40ml 5tk; 25mg 1ml 20ml 1tk; 25mg 1ml 40ml 10tk
efigalo kõvakapsel
krka, d.d., novo mesto - fingolimood - kõvakapsel - 0,5mg 60tk; 0,5mg 30tk; 0,5mg 98tk; 0,5mg 28tk; 0,5mg 14tk; 0,5mg 90tk; 0,5mg 100tk
jayempi
nova laboratories ireland limited - azathioprine - transplantaadi tagasilükkamine - immunosupressandid - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.
inzolfi kõvakapsel
sandoz pharmaceuticals d.d. - fingolimood - kõvakapsel - 0,25mg 28tk
varizig süstelahus
cangene corporation - tuulerõugete immunoglobuliin - süstelahus - 125rÜ 1.2ml 1.2ml 1tk
variquin süstelahus
sanquin, clb, products division - tuulerõugete immunoglobuliin - süstelahus - 100rÜ 1ml 2ml 1tk
varitect infusioonilahus
biotest pharma gmbh - tuulerõugete immunoglobuliin - infusioonilahus - 25rÜ 1ml 5ml 1tk
aciclovir siromed kreem
stada arzneimittel ag - atsikloviir - kreem - 50mg 1g 2g 1tk